Trial Profile
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Olinciguat (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Acronyms STRONG-SCD
- Sponsors Cyclerion Therapeutics; Ironwood Pharmaceuticals
- 01 Dec 2020 This trial has been Discontinued in United Kingdom, according to European Clinical Trials Database record.
- 14 Oct 2020 According to a Cyclerion Therapeutics media release, Results did not demonstrate adequate activity to support further internal clinical development. Company intends to complete its analysis of the study results and present or publish them in a future forum.
- 14 Oct 2020 Results presented in a Cyclerion Therapeutics Media Release.